SCHEMBL2290813

SCHEMBL2290813

C[N]Cc1ccc(F)cc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.49
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40
DCLRE1B Q9H816 1/20 0.38
NOTUM Q6P988 2/20 0.37
CLCN2 P51788 1/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
DHFR P00374 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36
TTR P02766 1/20 0.36
ALB P02768 1/20 0.36
HMGB1 P09429 1/20 0.36
CXCL12 P48061 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292800 0.82 GAA (0.41) KEAP1CES2CES1KDM4EALDH1A1
SCHEMBL8576783 0.82 KEAP1 (0.55) KEAP1CES2CES1DCLRE1BNOTUM
SCHEMBL4146826 0.78 KEAP1 (0.55) KEAP1CES2CES1DCLRE1BNOTUM
SCHEMBL11777759 0.77 KEAP1 (0.50) KEAP1CES2CES1DCLRE1BNOTUM
SCHEMBL150440 0.77 KEAP1 (0.53) KEAP1CES2CES1DCLRE1BNOTUM
SCHEMBL13806627 0.77 KEAP1 (0.53) KEAP1CES2CES1DCLRE1BNOTUM
SCHEMBL1021069 0.77 KEAP1 (0.53) KEAP1CES2CES1DCLRE1BKDM4E
SCHEMBL2290818 0.76 KEAP1 (0.49) KEAP1CES2CES1DCLRE1BKMT2A
SCHEMBL15592320 0.76 KEAP1 (0.49) KEAP1CES2CES1DCLRE1BNOTUM
SCHEMBL6756787 0.76 KEAP1 (0.49) KEAP1CES2CES1DCLRE1BNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008287-B2 Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one GILEAD SCIENCES, INC. (US) 2011-08-30 US claimed
US-20090306054-A1 INTEGRASE INHIBITORS GILEAD SCIENCES ,INC. (US) 2009-12-10 US claimed
EP-2066670-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-06-10 EP claimed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US claimed
WO-2007136714-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2007-11-29 WO claimed
US-8008287-B2 Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one GILEAD SCIENCES, INC. (US) 2011-08-30 US disclosed
US-20090306054-A1 INTEGRASE INHIBITORS GILEAD SCIENCES ,INC. (US) 2009-12-10 US disclosed
EP-2066670-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2009-06-10 EP disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
WO-2007136714-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058315-A1 Integrase inhibitors TYMP, DNTT, PAICS KEAP1 4299/4885CES2 381/4885CES1 730/4885
US-20090306054-A1 INTEGRASE INHIBITORS TYMP, POLR2E, CCNI KEAP1 4110/4885CES2 399/4885CES1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.